Palisade Bio, Inc.
General ticker "PALI" information:
- Sector: Health Care
- Industry: Pharmaceuticals
- Capitalization: $1.4M (TTM average)
Palisade Bio, Inc. follows the US Stock Market performance with the rate: 25.2%.
Estimated limits based on current volatility of 6.8%: low 1.63$, high 1.87$
Factors to consider:
- Total employees count: 9 (-25.0%) as of 2023
- Top business risk factors: Substantial doubt about continuing as a going concern, Operational and conduct risks, Dependence on single product candidate, Regulatory and compliance, Third-party risks
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [1.30$, 4.57$]
- 2025-12-31 to 2026-12-31 estimated range: [0.95$, 3.33$]
Financial Metrics affecting the PALI estimates:
- Positive: with PPE of -0.2 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -498.38 <= 0.33
- Positive: Investing cash flow per share per price, % of 0 > -0.66
- Positive: Inventory ratio change, % of 0 <= 0
- Positive: Shareholder equity ratio, % of 68.86 > 63.39
- Negative: negative Net income
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term PALI quotes
Long-term PALI plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.25MM | $0.00MM |
| Operating Expenses | $15.72MM | $13.32MM | $14.86MM |
| Operating Income | $-15.72MM | $-13.07MM | $-14.86MM |
| Non-Operating Income | $1.46MM | $0.77MM | $0.42MM |
| Interest Expense | $0.01MM | $0.01MM | $0.01MM |
| R&D Expense | $6.55MM | $6.89MM | $9.06MM |
| Income(Loss) | $-14.26MM | $-12.30MM | $-14.44MM |
| Profit(Loss)* | $-14.26MM | $-12.30MM | $-14.44MM |
| Stockholders Equity | $12.48MM | $11.31MM | $7.49MM |
| Assets | $15.76MM | $14.05MM | $10.88MM |
| Operating Cash Flow | $-13.36MM | $-11.13MM | $-12.19MM |
| Capital expenditure | $0.01MM | $0.00MM | $0.00MM |
| Investing Cash Flow | $-0.01MM | $-0.00MM | $0.00MM |
| Financing Cash Flow | $15.26MM | $11.19MM | $9.58MM |
| Earnings Per Share** | $-16.20 | $-26.97 | $-10.20 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.